

This is a repository copy of *Modelling the health and economic impacts of different testing and tracing strategies for COVID-19 in the UK*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/202226/>

Version: Published Version

Article:

Colbourn, Tim, Waites, William, Manheim, David et al. (24 more authors) (2020) Modelling the health and economic impacts of different testing and tracing strategies for COVID-19 in the UK. F1000research. 1454. ISSN 2046-1402

<https://doi.org/10.12688/f1000research.27980.1>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



RESEARCH ARTICLE

Modelling the health and economic impacts of different testing and tracing strategies for COVID-19 in the UK [version 1; peer review: 1 not approved]

Tim Colbourn ¹, William Waites ², David Manheim ^{3,4}, Derek Foster⁵, Simone Sturniolo⁶, Mark Sculpher⁷, Cliff C Kerr⁸, Greg Colbourn⁹, Cam Bowie^{10,11}, Keith M Godfrey^{12,13}, Julian Peto¹⁴, Rochelle A Burgess¹, David McCoy¹⁵, Nisreen A Alwan^{13,16}, Guiqing Yao¹⁷, Kang Ouyang¹⁸, Paul J Roderick¹⁶, Elena Pizzo¹⁹, Tony Hill²⁰, Nuala McGrath¹⁶, Miriam Orcutt ¹, Owain Evans²¹, Nathan J Cheetham²², Chris Bonell¹⁴, Manuel Gomes¹⁹, Jasmina Panovska-Griffiths^{1,19,23}, Rosalind Raine¹⁹

¹UCL Institute for Global Health, London, UK

²School of Informatics, University of Edinburgh, Edinburgh, Scotland, UK

³University of Haifa Health and Risk Communication Research Center, Haifa, Israel

⁴DaySooner, Delaware, USA

⁵Rethink Priorities, Redwood City, CA, USA

⁶Scientific Computing Department, Science and Technology Facilities Council, Harwell, UK

⁷Centre for Health Economics, University of York, York, UK

⁸Institute for Disease Modeling, Bill and Melinda Gates Foundation, Seattle, WA, USA

⁹Centre for Enabling EA Learning & Research, Blackpool, UK

¹⁰Director of Public Health (retired), and Professor of Community Health, Malawi, Taunton, UK

¹¹Professor of Community Health (retired), College of Medicine, University of Malawi, Blantyre, Malawi

¹²The Queen's College, Oxford University, Oxford, UK

¹³MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

¹⁴NIHR Southampton Biomedical Research Centre, University of Southampton, Southampton, UK

¹⁵London School of Hygiene and Tropical Medicine, London, UK

¹⁶Queen Mary University London, London, UK

¹⁷School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, UK

¹⁸University of Leicester, Leicester, UK

¹⁹Institute of State Governance, and Institute of Philosophy, Huazhong University, Wuhan, China

²⁰Department of Applied Health Research, UCL Institute of Epidemiology and Population Health, London, UK

²¹Independent public health consultant and health strategist. Retired Director of Public Health, Lincolnshire, UK

²²Future of Humanity Institute, Oxford University, Oxford, UK

²³WEL Clinical Commissioning Groups, East London Health and Care Partnership, London, UK

V1 First published: 14 Dec 2020, 9:1454
<https://doi.org/10.12688/f1000research.27980.1>

Latest published: 14 Dec 2020, 9:1454
<https://doi.org/10.12688/f1000research.27980.1>

Open Peer Review

Approval Status 

Abstract

Background: Coronavirus disease 2019 (COVID-19) is resurgent in the UK and health and economic costs of the epidemic continue to rise.

There is a need to understand the health and economic costs of different courses of action.


Methods: We combine modelling, economic analysis and a user-friendly interface to contrast the impact and costs of different testing strategies: two levels of testing within the current test-trace-isolate (TTI) strategy (testing symptomatic people, tracing and isolating everyone) and a strategy where TTI is combined with universal testing (UT; *i.e.* additional population testing to identify asymptomatic cases). We also model effective coverage of face masks.

Results: Increased testing is necessary to suppress the virus after lockdown. Partial reopening accompanied by scaled-up TTI (at 50% test and trace levels), full isolation and moderately effective coverage of masks (30% reduction in overall transmission) can reduce the current resurgence of the virus and protect the economy in the UK. Additional UT from December 2020 reduces the epidemic dramatically by Jan 2021 when combined with enhanced TTI (70% test-trace levels) and full isolation. UT could then be stopped; continued TTI would prevent rapid recurrence. This TTI+UT combination can suppress the virus further to save ~20,000 more lives and avoid ~£90bn economic losses, though costs ~£8bn more to deliver. We assume that all traced and lab-confirmed cases are isolated. The flexible interface we have developed allows exploration of additional scenarios, including different levels of reopening of society after the second lockdown in England as well as different levels of effective mask coverage.

Conclusions: Our findings suggest that increased TTI is necessary to suppress the virus and protect the economy after the second lockdown in England. Additional UT from December 2020 reduces the epidemic dramatically by Jan 2021 and could then be stopped, as continued TTI would prevent rapid recurrence.

Keywords

COVID-19, Test, Trace, Isolate, UK, Health, Economic, Impacts, Mathematical Model





This article is included in the [Coronavirus](#) collection.



This article is included in the [University College London](#) collection.

1

version 1 
14 Dec 2020 [view](#)

1. **Katharina Hauck** , Imperial College
London, London, UK

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Tim Colbourn (t.colbourn@ucl.ac.uk)

Author roles: **Colbourn T:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Waites W:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Manheim D:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Foster D:** Conceptualization, Data Curation, Formal Analysis, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Sturniolo S:** Conceptualization, Formal Analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Sculpher M:** Conceptualization, Investigation, Methodology, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Kerr CC:** Investigation, Software, Validation, Visualization, Writing – Review & Editing; **Colbourn G:** Data Curation, Formal Analysis, Investigation, Project Administration, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Bowie C:** Conceptualization, Data Curation, Formal Analysis, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Godfrey KM:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Peto J:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Burgess RA:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **McCoy D:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Alwan NA:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Yao G:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Ouyang K:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Roderick PJ:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Pizzo E:** Data Curation, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Hill T:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **McGrath N:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Orcutt M:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Evans O:** Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Cheetham NJ:** Data Curation, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Bonell C:** Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Gomes M:** Conceptualization, Data Curation, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Panovska-Griffiths J:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Raine R:** Conceptualization, Investigation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: WW acknowledges support from the Chief Scientist Office (COV/EDI/20/12). RR, JPG, and EP are supported by the National Institute for Health Research ARC North Thames. NMCG is a recipient of an NIHR Global Health Research Professorship award (Ref: RP-2017-08-ST2-008). NAA receives research support from NIHR Applied Research Collaboration Wessex and NIHR Southampton Biomedical Research Centre. The views expressed in this independent research are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. KMG is supported by the UK Medical Research Council (MC_UU_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-10042) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)), British Heart Foundation (RG/15/17/3174), and the US National Institute On Aging of the National Institutes of Health (Award No. U24AG047867). GY acknowledges her research partially supported from the Newton Fund through a UK-China ARM Partnership Hub award (No:MR/S013717/1). DF is supported by Rethink Priorities (www.rethinkpriorities.org). All other authors declare that no specific grants were involved in supporting their time on this work. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2020 Colbourn T *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Colbourn T, Waites W, Manheim D *et al.* **Modelling the health and economic impacts of different testing and tracing strategies for COVID-19 in the UK [version 1; peer review: 1 not approved]** F1000Research 2020, 9:1454 <https://doi.org/10.12688/f1000research.27980.1>

First published: 14 Dec 2020, 9:1454 <https://doi.org/10.12688/f1000research.27980.1>

Introduction

In the UK, since the first confirmed case of coronavirus disease 2019 (COVID-19) on January 31, 2020, over 1,538,000 people have tested positive and over 55,838 deaths have been confirmed as of November 24, 2020¹ with a notable resurgence in the number of cases and deaths from September 2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, can be transmitted through inhaling viral droplets from an infectious person², but infection by fomites³ and aerosols⁴ may also occur. Reducing contact via testing, tracing and isolation (TTI), restrictions on social contact (*i.e.* lockdown measures), instigating good hygiene and ventilation, and the use of face coverings (masks) are now widely used non-pharmaceutical interventions (NPIs) to reduce COVID-19 transmission. The magnitude of benefit varies between interventions, with emerging evidence from laboratory experiments⁵⁻⁷, clinical studies⁸⁻¹⁰, and epidemiological studies¹¹⁻¹⁵ that face masks reduce infection risk.

Following the resurgence in COVID-19 cases since September 2020 in the UK, the UK Government imposed a second lockdown in England from November 5, 2020 to suppress transmission and prevent hospitals being overwhelmed (the devolved governments in Wales and Northern Ireland introduced lockdowns in October and Scotland introduced additional restrictions in November). While rollout of an effective vaccine is awaited, intermittent lockdown may remain the main tool for SARS-CoV-2 suppression. But lockdown strategies have important economic, educational, social and psychological consequences¹⁶. Alternative means of SARS-CoV-2 suppression such as via effective TTI and high coverage of face masks are required to balance protecting the public from COVID-19 resurgence with protecting the economy and reopening society. Our study is the first that attempts to shed light on this question by combining epidemiological modelling with economic analysis.

Since the onset of the pandemic, modelling has played an important role in understanding COVID-19 epidemic trends as well as assessing the effectiveness of different intervention strategies¹⁷⁻²¹. For example, recent modelling work¹⁹ highlighted the need for an effective TTI programme that tests sufficient numbers of people with symptoms, traces their contacts effectively and ensures they isolate to prevent COVID-19 resurgence, as schools reopened alongside society from September 2020. However, this study did not include an economic analysis. In fact, to our knowledge, only two models to date have considered the economic consequences of different interventions combined with projecting model outcomes from a model of disease progression, and neither are focused on the UK^{22,23}. This is challenging because uncertainties in data and calibration are magnified when composing models: a combined model can contain more uncertainty than the individual model due to propagation of uncertainties. For example, balancing a detailed model of transmission and a detailed model of cost-effectiveness or net-benefit is very data reliant, but in the context of COVID-19, information on both fronts is scarce, though emerging.

In this study, we handle these limitations by directing our focus on understanding the most important features of the combined model. We use a Susceptible-Exposed-Infectious-Removed (SEIR) model²⁴ and a simplified economic analysis to explore the pattern of infections and deaths from COVID-19 and the economic impact of different NPIs in the UK. To make a wide range of scenarios accessible, we provide a user-friendly web interface that allows policymakers to explore trade-offs between different scenarios. This tool is aimed to facilitate discussion of key proposed high-level policies and their impacts based on an easily comprehensible model. This is opposed to static pronouncements about the optimal reaction, in which a complex model such as Covasim used in Panovska-Griffiths *et al.*¹⁹ must be used to accurately represent the complexity of the projected course of the disease. Importantly, for the first time, we contrast TTI strategies that test only symptomatic people and trace their contacts, with combined TTI and additional universal testing (combined TTI+UT). We also look at the role of face masks in suppressing the epidemic in conjunction with TTI and UT.

On September 09, 2020, the UK government announced that universal testing added to the current TTI strategy was being considered as an option to reopen society. In general, a universal testing programme might include more frequent and mass testing, *e.g.* at schools, and before concerts and sports matches, as suggested in recent reports from the Scientific Advisory Group for Emergencies (SAGE), which advises the UK Government²⁵. But it can also mean repeated testing of the entire population. In this paper, under our definition, universal testing (UT) means testing everyone routinely, in contrast to testing only people with COVID-19 symptoms (we assume 70% of cases are symptomatic^{19,26-28}). Weekly SARS-CoV-2 testing of the entire population was proposed for the UK earlier in the epidemic²⁹, via saliva testing³⁰ that is now being piloted³¹, and has been followed by the recent initiative of the UK Government to undertake mass-testing in high-prevalence local authority areas³². Similar universal testing strategies have also been proposed for the USA^{33,34}.

This study combines mathematical and economic modelling to contrast the health impact, in terms of mortality burden, the economic outcomes, in terms of economic costs of shutdowns and isolation, and the direct costs of targeted TTI strategy in absence and in presence of additional UT (TTI+UT strategy). For each testing strategy we model reopening of society with the contact rate increasing from December 02, 2020 to that before the lockdown in November 2020. The contact rate is defined as the daily number of contacts per person and assumed to be around 11 contacts per person in the pre-COVID-19 era³⁵. For each scenario we incorporate the use of face masks under assumptions of mean effective coverage (EC), which is the product of the efficacy of face masks and the proportion of contacts in which they are worn (details on methods and sensitivity analysis are in Methods, at the end of the article).

Results

The results of the modelling and economic analysis are shown in [Figure 1](#) and [Table 1](#). The graphs in [Figure 1](#) were generated with [Streamlit](#).




Figure 1. Model-predicted outcomes for three different testing and tracing strategies simulated to start after the lifting of the second lockdown in England (from December 02, 2020) in presence of masks with moderate (30%) effective coverage. Figure 1A (top): Scenario 1: Base testing scenario (Base Testing, Tracing and Isolation (TTI)), Testing level of 25%, tracing level of 50% and assumed full isolation. Figure 1B: Scenario 2: Enhanced symptomatic testing (Enhanced TTI), Testing level of 50%, tracing level of 50% and assumed full isolation. Figure 1C (bottom): Scenario 3: Enhanced symptomatic and asymptomatic testing (TTI + Universal Testing (UT)) Testing level of 70%, tracing level of 70% and assumed full isolation. Figures were generated under the combination of parameters that define these scenarios as described in the methods and using the [Streamlit](#) interface.

The modelling suggests that TTI interventions might prevent future epidemic waves if enough symptomatic people are tested and their contacts effectively traced and all isolated, in combination with at least moderate effective coverage (30% in our case) of masks (Figure 1A).

Specifically, if only 25% of symptomatic people are tested, and 50% of their contacts are traced and all isolated, (Figure 1A), then following the second lockdown in England, an increase in the number of cases is evident. This will push the effective reproduction number R above 1 and the epidemic will persist.

To prevent this, an adequate level of testing of symptomatic people is necessary; in Figure 1B we show the outcomes when the testing level is doubled to 50%, while tracing level remains the same as before (50%) and full isolation of people tested and their contacts is assumed. In this scenario, we see the declining trajectory in the number of cases in January 2021 onwards and the effective reproduction number dropping below 1.

The results for TTI+UT are shown in Figure 1C. In order for the predicted epidemic trajectory to decrease rather than increase after the second lockdown in England and from December 2020, even with nearly universal weekly testing, additional symptomatic testing and tracing is necessary. In Figure 1C we show the combination of 70% testing and 70% tracing that, for this combination of parameters, is necessary to suppress the virus in future and bring R rapidly down.

Overall, increasing TTI testing clearly reduces the future mortality burden: the model projects 110,000 deaths with adequate TTI (50% testing of symptomatic, 50% tracing of their contacts and isolating all) compared to 140,000 deaths with weaker testing (25% testing and same trace-isolate assumptions), by May 31, 2021 (Table 1). Additional UT will reduce this

burden even further: 90,000 deaths are predicted in this scenario by the end of May 2021.

Considering the economic impacts, increasing the TTI from testing 25% to 50% of symptomatic people reduces the economic loss (£543 billion vs £541 billion by the end of May 2021; Table 1). Additional UT reduces the economic loss further (£454 billion by the end of May 2021). Across all scenarios the majority of costs incurred are for tracing, whereas UT naturally has much higher testing costs (Table 1).

Discussion

Overview of results

This work combined epidemiological modelling with economic analysis and developed a user-friendly interface to project our results. We simulated different testing strategies after the lifting of the second lockdown in England in December 2020. Our findings suggest that loosening restrictions accompanied by scaled-up TTI (50% testing of symptomatic people, 50% tracing of their contacts and full isolation of those tested positive and their contacts) and moderate (30%) effective coverage of masks can significantly further limit spread of COVID-19 after the second lockdown, and protect the economy in the UK. Additional weekly universal testing of the entire population from December 2020, can suppress the virus further, save more lives, and avoid more economic losses, though costs more to deliver. To achieve this, UT would have to be combined with additional TTI covering symptomatic cases (70% testing of symptomatic, 70% of their contacts traced and full isolation), and combined TTI+UT is more costly than scaled-up TTI.

Strengths

The particular value and novelty of our work lies both in combining the epidemiological impact with an economic model and in the comparison between two different testing strategies that are currently being considered by the UK Government.

Table 1. Model-predicted outcomes by May 31, 2021 for impact and costs under three different testing strategies simulated to start after the lifting of the second lockdown in England (from December 02, 2020) in presence of masks with moderate (30%) effective coverage.

	Scenario 1: Base testing scenario (Base TTI) Testing level of 25%, tracing level of 50%.	Scenario 2: Enhanced symptomatic testing (Enhanced TTI) Testing level of 50%, tracing level of 50%.	Scenario 3: Enhanced symptomatic and asymptomatic testing (TTI+UT) Testing level of 70%, tracing level of 70%.
Total COVID-19 Deaths	140,000	110,00	90,000
Economic Loss (GDP reduction) from Shutdown and Isolation	543 billion GBP	541 billion GBP	454 billion GBP
Total Tracing Cost	15.0 billion GBP	13.0 billion GBP	14.0 billion
Maximum Tracers Needed	160,000	140,000	160,000
Total Testing Cost	45.1 million GBP	54.9 million GBP	6.89 billion GBP
Maximum Daily Tests	69,000	69,000	10.0 million

Our epidemiological model, described in detail in a separate paper²⁴ is a version of the classic population-based SEIR model extended to include different testing and tracing strategies. SEIR models are well-established as a tool in modelling infectious diseases and have been widely used in modelling different COVID-19 questions³⁶. Our economic model represents a simple economic analysis developed explicitly for this study to capture public sector costs of testing and tracing and wider economic impacts of shutdown and isolation. Our approach is deliberately simple and our interface is easy to use.

Model limitations and simplifications

The epidemiological model is readily extendable to include varying degrees of symptomaticity, including the pre-symptomatic period and its duration, varying amounts of viral load correlated with levels of transmission, infectiousness levels, duration of exposure, infectiousness period, and test sensitivity. It can also be easily adapted to include different age and risk stratifications, describe more elaborate representation of the natural history of the disease and progression among different subpopulations, and indeed how contact and transmission varies among and across different cohorts. One aspect that needs to be explored further in future is our modelling assumption of perfect isolation following tracing. Adherence to isolation is an important aspect of a TTI strategy and the balance between testing, tracing and isolation levels needs to be untangled more. But this was beyond the scope of this paper. Finally, uncertainty can be added to the model by setting parameter distributions. But all of these complications add different levels of nonlinearity, which makes the model multidimensional and makes it more difficult to untangle the real contribution of various factors. Our intention was to keep the epidemiological model as simple as possible and combine with economic modelling. For this reason, we also do not consider spatial variation, the difference between cities and rural settings, or epidemics developing in different ways in different regions. For this study, we chose to focus specifically on testing, tracing and isolation, and the trade-offs between different strategies at an aggregate level. An important reason for this is the difficulty of obtaining sufficient good quality data with which to parametrise a more sophisticated model: doing so would have no guarantee of accuracy and risks distracting from our central point. Future work could usefully examine the extent to which the present conclusions hold in more complex models.

In particular, our model does not model specific populations at heightened risk of COVID-19 infection or death, *e.g.* males, people of black, Asian or mixed ethnicity, or people with co-morbidities³⁷. Future work could look at risk-group and/or geographical stratification within the model, but this was beyond the scope of this study. Recent work has identified additional population cohorts, *e.g.* people with multiple morbidities or learning disabilities, and people at heightened risk of hospitalisation, intensive care unit admission and death from COVID-19³⁸. Future extension of the work presented in this paper will combine these findings with the modelling and economic framework developed here, to explore the health impact and economic outcomes of different testing interventions on

cohorts at higher risk from COVID-19. This will allow us to extend our outcome measures. We limited our examination of health outcomes to direct mortality, but recognise that chronic illness and organ damage from COVID-19³⁹ may have long-term effects not only on the health and well-being of the people affected, but that COVID-19 also creates many second order impacts including but not limited to damage to the economy longer term, impacts on mental health, and social structures. We have not included these outcomes in order to keep the modelling framework as simple as possible, so our conclusions on the potential benefits of different interventions are likely to be conservative.

Our economic model does not explicitly model any costs to enforce isolation, or costs to provide separate accommodation for people to isolate in. We also assume perfect isolation in our model and future work will explore this further²⁷. Policies to support effective isolation, such as lost income reimbursement, community support, childcare, online education, and volunteers to run errands for those isolated, are important. Costs of enforcement may be covered by a combination of using existing policing systems and paying for additional measures with fines gathered from violators.

Despite omission of important details such as detailed modelling of household and community layers, and assuming perfect isolation policies, the model indicates some priorities for immediate piloting with transparently calculated cost estimates. Tracing should focus on how to improve actual isolation rates among all recent contacts, not on targets. An important implication is that with high compliance regular testing might end the need for social distancing and should therefore be properly piloted. To minimise unnecessary isolation and encourage compliance the rapid tests that will be available to NHS and care home staff could be offered daily to anyone in isolation. Automatic payment of (say) £500 initially then £100 per day might achieve high compliance with isolation in those at highest risk including the unemployed and homeless. Average isolation until 2 or 3 days between negative tests would be about 3 days for uninfected contacts and up to 10 days for cases, so the average cost of full furlough would be less than £1,000 per person. Furlough for 10 times the half a million or so adults currently infected in the UK at an average of less than £1,000 would cost less than £5 billion and should be considered.

Conclusions

In summary, we have combined epidemiological modelling, economic analysis and a user-friendly interface to contrast the impact and costs of two levels of testing and tracing within the current UK TTI strategy and when universal testing is also included. Our findings suggest that increased TTI is necessary to suppress the virus after the second national lockdown in England. With reopening of society in December 2020, as before the second lockdown, scaled-up TTI and moderate (30%) effective coverage of masks can prevent further resurgence of the virus and protect the economy in the UK. Additional universal testing from December 2020 can save more lives and avoid more economic losses.

Methods

Mathematical model for transmission of SARS-CoV-2

The model is available from [GitHub](#) and is archived with [Zenodo](#)⁴⁰. The impact analysis was conducted using the SEIR-TTI compartmental model shown schematically in [Figure 2](#) and with details provided in [Sturniolo *et al.*](#)²⁴ The model is an extended version of the classic SEIR model that incorporates probabilistically the effects of testing, contact tracing, and isolation²⁴.

Within the model, possible transitions between cohorts are indicated with arrows. Within each of these states, an individual can be unconfined or isolated. Infectious (I) individuals who are unconfined may be tested and become isolated. An individual in any state who is traced is isolated. Once isolated, individuals remain so for 14 days. Susceptible (S) isolated individuals cannot become infected due to their isolation, and return to the unconfined state after a 14-day delay. Exposed (E) and infectious individuals (I) do not return directly to the unconfined state and first progress to removed (R). Removed (R) and isolated individuals return, as with susceptible (S) individuals, to an unconfined state once 14 days has elapsed. Tracing is described by a rate of tracing *eta* and a probability of success *chi*.

Model parameters and details of the calibration used are detailed below. Briefly, the model-projected deaths between January 21, 2020 and November 07, 2020 were matched to the publicly-available data on deaths reported within 28 days of positive tests, using [the UK dashboard](#). This allowed us to determine the transmission probability *beta*, the numbers of contacts, the date of the onset of the epidemic, number of infectious people at the onset of the epidemic, the infection fatality rate (IFR) and the testing and tracing levels to constrain the model to mimic the reality of the COVID-19 epidemic in the UK until November 07, 2020.

We note that within the model an intervention changes the model parameters at a defined time. The principal parameters that are changed are the contact rate (average number of contacts per person per day) representing differing regimes of social distancing or lockdown, and the testing and tracing rates, representing building up capacity of TTI. A trigger changes parameters when a condition is met. The trigger conditions are the number of infections passing a set threshold. We use different thresholds according to whether the number of infections is increasing or decreasing to avoid rapidly oscillating between distancing regimes, which would not be politically or economically feasible. We use a threshold of < 10,000 infections to release lockdown as it approximates what may be a safe level of limited community transmission. We use a threshold of > 40,000 infections for beginning lockdown to reflect time elapsing between opening and closing given exponential growth. Lockdowns are not triggered in the scenarios shown in this paper.

Economic model overview

We developed an economic model based on closures and isolation that uses the impacts from the SEIR-TTI model to calculate the cost on the economy⁴¹. Specifically, within the economic model we modelled GDP reduction as a function of the reduced contact rate and isolation requirements. That means reduced economic activity was modelled when people stay at home, rather than shop, work, or engage in other economic activities, as during the lockdown period for example. Because there are already estimates about the degree of contraction which occurred during the lockdown (*e.g.* from the Bank of England), we use reduction in interpersonal contacts as a valid proxy for the proportion of full shutdown effectively continuing to occur. This is more closely related to the epidemic evolution than direct estimates of shocks to supply and demand used in the past⁴², and has the advantage of using actual estimates of the economic impact of COVID-19 based on mitigation




Figure 2. Schematic of an SEIR model with diagnosis described by testing and contact tracing. SEIR is a compartmentalised model describing susceptible (S), exposed (E; infected but not infectious), infectious (I) and removed (R) population cohorts. Individuals move between these compartments in sequence as they become exposed, infected and infectious during disease progression until recovery. Each compartment comprises diagnosed (D) and undiagnosed (U) individuals with diagnosis leading to isolation. We assume that diagnosis happens through testing or putatively through tracing. A non-infectious individual that is “diagnosed” has effectively been misdiagnosed and the result is that they are needlessly required to isolate. Individuals transition between compartments X and Y at rates $\Delta_{X \rightarrow Y}$ which we derive in [Sturniolo *et al.*](#)²⁴ from which this figure is reproduced.

policy choices. Our economic model is further detailed below. Potential health and social costs of lockdown that are not included in our economic model are shown in [Table 2](#) below.

Realising resources required for TTI and UT

Estimated costs for TTI and UT are shown in [Table 3](#) below. There are three principal components, which we also explain in detailed narratives below: (1) contact tracing using a network of public health community officers, mobile phone apps, and supervisors; (2) home-based saliva testing for active SARS-CoV-2 infection; and (3) follow-up and isolation of infected individuals and households. As per the economic model, total costs are variable depending on policy scenario and case numbers.

Modelled scenarios

We contrasted three testing strategies from December 02, 2020 when the second lockdown in the England is lifted. Specifically, we compared the impact and costs of

A) Baseline targeted test-trace-isolate (TTI) strategy from December 02, 2020 resembling the current strategy that tests only symptomatic people, traces their contacts and isolates those testing positive and their contacts. We model 25% testing, 50% tracing and full isolation.

B) Enhanced TTI strategy from December 02, 2020 modelled by increased testing level compared to the baseline TTI. We model 50% testing, 50% tracing and full isolation.

B) Universal testing in addition to the targeted TTI strategy from December 02, 2020. We model 70% testing across symptomatic and asymptomatic, 70% tracing of their contacts and full isolation.

For each of the strategies we include wearing masks and that the contact rate c increases to a value of 3.4 as the average c of the values between 2.8 and 4 from the CoMix study⁴³ representing the values during the first lockdown and after the relaxing of it. While in this paper we present the results for a moderate effective coverage of masks, lower and higher effective coverage can be explored further on [our interface](#).

Face masks scenarios

On the interface that we have developed, we modelled three different levels of effective coverage of masks (defined as the size of the reduction in COVID-19 transmission in the population as a whole due to the use of face masks): 15%, 30% and 50%. These were estimated as a product of contact coverage (the proportion of infectious-susceptible contacts in which at least one person is wearing a mask), and per-contact effectiveness (the size of the risk reduction when at least one person is masked). Surveys and media reports suggest mask prevalence outside the home is around 40–80%^{44–47}. Assuming no mask usage within the home, and 3–8 daily contacts of which 1–3 are at home³⁴, population-wide prevalence is 30–60%. In a well-mixed population, this translates to contact coverage of 45–85%, because in many contacts involving unmasked individuals the other party will be wearing a mask. Reviews of mask effectiveness

suggest a benefit of approximately 45% for uninfected wearers in non-healthcare settings, with a plausible range of about 20–70%^{8–10}. Since these were mostly case-control studies, we adjust downwards for biases that may have inflated the effect size, and for mask type: most people in the UK use cloth masks⁴⁸, which are probably less effective than the medical masks used by some participants in the reviewed studies^{7,8,49,50}. However, we then adjust upwards for source control, which is hard to quantify but has been clearly demonstrated in the laboratory^{5–7}. Taking all of this into account, and weighting by the proportion of single- and double-masked contacts, we end up with an effect size of 20–60%. Multiplying that by the contact coverage, we obtain an effective coverage estimate of 30%, with a range of 15–50%.

In the paper we present the results for this moderate 30% EC of masks, but the other scenarios can be explored on the interface described below.

Interface description

The epidemiological model and the economic framework were combined into a user-friendly interface that we developed for the purpose of this analysis. The interface is available on [Streamlit](#) and the figures in this manuscript were directly imported from the interface plots. Within the interface there are clickable options that allow the user to explore different permutations of the scenarios we have considered in this study; a snapshot is shown in [Figure 3](#).

Epidemiological model and calibration

Details of the compartmental SEIR-TTI model we used for the impact analysis are in [Sturniolo *et al.*²⁴](#) In summary, it is an extended version of the classic SEIR model that incorporates probabilistically the effects of testing, contact tracing, and isolation. For the purposes of the analysis here, we fixed the majority of the model parameters to the values from the literature as per [Table 4](#). We fitted the four parameters: transmission probability β , the rate of contacts, the date of the onset of the epidemic, number of infectious people at the onset of the epidemic and the infection fatality rate (IFR) to match the model projected deaths to the publicly available mortality data from [the UK government](#). To match the UK epidemic, we consider a single infectious individual introduced into the UK in late December 2019. This is simply a mathematical convenience and not a claim about the seeding of the actual epidemic in the UK. It is not our purpose to investigate the origins of the epidemic in this article. In reality it is likely that multiple infectious individuals were introduced into the UK at a later date. This distinction is immaterial to the functioning of the model. By calibrating to the mortality data, we obtain a transmission probability β of 0.0435 which translates to a basic reproduction number R_0 of 3.3 when c is 11 contacts per day and under no interventions. The results of the calibration are shown in [Figure 4](#) and further details are provided [here](#).

Economic model details

Reduction in GDP

We calculate reduction in GDP due to the pandemic and lockdown measures by relating GDP to the model parameter c

Table 2. Potential Health and Social Impacts of COVID-19 lockdown and impact on NHS of COVID-19 demand⁵¹.

Sector			Processes affected	Potential adverse health outcome
NHS	Programmes	Screening across the life course, e.g. neonatal, cancer	Delivery, uptake and action ^{52,53}	Avoidable morbidity and mortality
		Immunisation	Reduced uptake ⁵⁴	Reduced herd immunity Increase in vaccine preventable infection
	Child and adolescent health		Health visitor checks and support for parents Adolescent mental health ⁵⁵ Safeguarding	Avoidable morbidity Increased violence against children/child abuse while in lockdown (particularly linked with alcohol, drug use)
	Maternal health	Antenatal care in pregnancy and post-natal follow up ⁵⁶	Birth experience Anxiety - giving birth alone/impact of self-isolation – reduced peer and family support for new mothers Missed risk factors and antenatal diagnoses	Adverse birth outcomes Postnatal depression
	Severe trauma		Still managed but Intensive Care Unit (ICU) availability may be stretched Secondary infection in hospital COVID-19 acquired	Avoidable morbidity and mortality
	Cancer	Potential new cancer Existing cases	Delay diagnosis and treatment Radiotherapy and chemotherapy	Avoidable morbidity and mortality
	Acute cardiovascular disease (CVD)		Still diagnosed and treated Secondary acquired in hospital COVID-19 ICU availability	Avoidable morbidity and mortality, including from delayed presentation to hospital for CVD/acute MI
	Other acute care (respiratory, fall, outpatients etc)		Diagnosis and treatment	Avoidable morbidity and mortality
	Chronic disease management		Less monitoring (e.g. hypertension, diabetes, asthma, epilepsy) Poorer control Access to medication Difficulty following healthy lifestyle advice	Avoidable morbidity and mortality ⁵⁷
	Elective surgery		Delayed, Quality of Life (QoL) may worsen, less operable if condition worsens. Backlog	Avoidable morbidity Poorer Quality of life
	Services for vulnerable groups	Homeless	Temporary housing provision, but often without access to food or basic necessities Lack of access to health services ⁵⁸ Disrupted support services during lockdown Removal of temporary housing at the end of COVID-19	Poorer health outcomes
		Dementia	Isolation, less carer support ⁵⁹ Harms e.g. falls	Poorer quality of life Higher morbidity and mortality
		Patients with disability	Access to services for complex medical needs ⁶⁰ Isolation Anxiety – may not be a 'priority' group for ICU Inequity in access to public health messaging	Worse health outcomes
		Severe mental illness (inpatient services)	Deterioration, potential relapse Loss of access to inpatient services (secondment of staff to Covid-related support) Reduced community mental health teams during lockdowns	Suicide Hospital Admission

Sector			Processes affected	Potential adverse health outcome
		Prisoners	Mental health, addiction Higher COVID-19 risk due to poor living conditions ⁶¹ Isolation (due to loss of visitation rights) Difficulty in isolation Risk of riots (like in Italian prisons)	
		Older people	Likely to live alone and have less access to online communication	Health impacts of isolation and loneliness
		Refugees and migrants	Exclusion of migrant populations from health services: in the UK NHS Charging Regulations deter migrants from accessing health services (particularly those undocumented) Culturally or linguistically inappropriate care Increased discrimination/xenophobia during COVID-19 ⁶² Difficulty in isolating or applying preventative interventions for those living in overcrowded conditions, intergenerational households, or those held in detention centres Low-wage migrant workers on precarious contracts	Poorer health outcomes Higher COVID-19 mortality for BAME groups ⁶³ Higher morbidity and mortality from COVID-19 due to delay in accessing health service/lack of access to health service/ inability to apply preventative interventions Higher exposure to COVID-19 if continuing to work as key worker during lockdown; additional adverse effects of loss of income if precarious employment
		Health and care staff	Post-Traumatic Stress Disorder (PTSD) Generalised Burnout	
	Diagnostic services X-Ray, Escopy		Delayed diagnosis and treatment	Poorer long-term outcomes (avoidable morbidity and mortality) - Costly for individuals and the NHS
	Rehab Physio/ Occupational Therapy		Poorer long-term outcomes	Increase in disability or duration of recovery, poorer quality of life – additional individual and societal costs
	Addiction services	Smoking cessation Alcohol Drugs	Some success with quitting Less support for dependent patients	Avoidable morbidity and mortality
	Sexual health services		Less access	Avoidable morbidity
	End of life care		Impact on hospices and care for those dying at home - reduced staff and funding Adverse grief reactions for bereaved relatives of COVID-19 patients - evidence suggests that there will be increased rates of PTSD and depression for those affected by COVID-19 related loss, as it is essentially a form of traumatic loss – unexpected and without closure.	
	Mental health services (common mental disorders)	Increased rates of suicide and self harm ⁶⁴ Increased rates of depression ⁶⁴ Increased rates of condition related anxiety (COVID patients) ⁶⁴	Difficulties accessing primary care for early diagnosis and treatment	Avoidable morbidity and mortality

Sector			Processes affected	Potential adverse health outcome
Social isolation and distancing measures	Household isolation		Less physical activity Mental health (stress, insomnia, anxiety, depression) Domestic abuse Family breakdown Elder abuse Safeguarding Loneliness Infection transmission from crowding Increased substance misuse Poorer diet (BMI impact, type 2 diabetes risk) Reduced access to medications Increased experiences of racialised policing (BME groups) Loss of access to public spaces (closure of parks likely to impact communities who live in crowded housing) Lack of access to free school meals for children who need them, and increased use of food banks	Depression Suicide Physical trauma Adverse impact on physical WB Increased falls in the elderly isolated at home Poor reporting of moderate health risks to health professionals (i.e. early signs of cancer, heart disease, etc)
	Access to food	Especially if vulnerable and isolating	Hunger, poor nutrition (both obesity and under-nutrition / vitamin deficiencies)	Adverse impact on mental and physical wellbeing and on child development
Transport	Less travel		Fewer accidents Less air pollution, including greenhouse gases	Less trauma from RTAs and therefore reduced admission to hospital Less cardiovascular, respiratory illness Less morbidity and mortality Increased health risks to those who continue support of essential transport services and their households
Employment /income loss	Household income loss on top of existing poverty especially those made unemployed, reduced hours outside Chancellor's support initiatives	Vulnerable groups for pre-existing poverty, low pay sectors (accommodation, catering, retail, care) Single mothers with children, People with disability, ethnic minorities	Food insecurity-hunger, nutrition Heating costs, cold related illness Mental health including alcohol and drug misuse (see above) Homelessness/loss of home Gambling Increased uptake of universal credit system due to lack of protection for economic shocks in poor households	Increased vulnerabilities Avoidable mortality and morbidity among already high-risk groups
School closure	Education		Loss of free school meals if not attending school Loss of regular physical activity Impact on social development and education (widening inequalities) Safeguarding	
	Higher education closure			
	Longer term wider inequality post COVID-19 ⁶²			

Table 3. PTTI Resources Required. Shown are unit/daily costs. Total costs are variable dependent on policy scenario and case numbers. *Costs of testing are based on a pilot study in Southampton of mass home-based saliva testing³¹.

1. Contact tracing					
Staff	Function	Number	Rationale for number	Salary per day	Notes
Public Health Community Officer	Trace contacts via apps and in person - follow-up to check isolation and re-testing	81463	1 per 1000 population (like community health workers in many countries) + 20% for sickness cover and absence	£80	These workers can be people who have lost their employment as a result of the pandemic, they will need minimum qualifications though no prior experience of public health work as can be trained
Public Health COVID-19 supervisor	Supervisor / manager for PHCOs - ~1 per 50, or ~4 per each of the 343 local authority areas	1629	these team leads will work full time answering queries from PCHO and helping resolve problems + 20% for sickness cover and absence	£160	These supervisors could be recent graduates of public health or related Masters courses, or local authority Environmental Health Officers.
Local authority team lead	One for each of the 343 Local authorities	412	1 for overall control of contact tracing effort for each local authority area + 20% for sickness cover and absence	£300	These team leads should be public health specialists with at least 5 years experience
Online training for all staff		1	Three training courses (including refreshers) one for each staff cadre. Assume repeated every 3 months		generously funded at £20,000 per online training course developed (can do on phones which will be used for contact tracing too) + £500 per month for running servers for online training
				Unit cost	
Recruitment costs	Recruitment costs for all contact tracing staff, including for replacements and cover (per 3-month period - conservative assumption is repeating this every 3 months even though the same tracers may be in post)	83504	£200 per recruitment for advertisements, phone interviews, salary of recruiters	£200	
Equipment	Function	Number	Rationale for number	Cost per day	Notes
Phone pay as you go credit	for calls and data for all staff including for online training	83,504	all staff above	£5	
				Unit cost	
Smart phones	only for ~10% of staff who don't have one	8,350	most people have smartphones in the UK	£200	
START-UP COSTS: Mobile phone app development	for rapid contact tracing given rapid spread	1	one app needs to be developed (or chosen from many already made?)	£10,000,000	ballpark estimate of developing, maintenance and running the app over a year
3 MONTH PERIOD COST: Mobile phone app maintenance and running costs	for rapid contact tracing given rapid spread		£1m per month estimate means £3m per 3 month period	£3,000,000	

1. Contact tracing					
Travel	Function	Number	Rationale for number	Cost per day	Notes
For supervisors and managers	to check work of PCHOs in person if needed	2,041	number of supervisors and managers	£10	Travel will be in local areas so costs per day for driving or public transport should not be high
For PCHO in rural areas	to get around to their whole catchment population of 1000 people	13,849	17% of UK population is rural so have this travel allowance for 17% of PCHO	£10	Travel will be in local areas so costs per day for driving or public transport should not be high
3 MONTH PERIOD COST: Communications	To advertise the contact tracing scheme and keep people informed of it	1	Estimated budget of £100,000 per day for advertising and communications. Advertising campaigns assumed to last for a minimum of 3 months	£9,125,000	This will be additional to national COVID-19 advertising budgets given current on-going COVID-19 advertising campaigns funded by the government
2. Testing - SARS-Cov-2 viral RNA RT LAMP tests, home saliva samples*					
Staff	Function	Number	Rationale for number	Salary per day	Notes
Lab technicians	running SARS-Cov-2 viral RNA RT LAMP tests	11,574	18 hrs per day, two 9 hrs shifts: 1 technician running one machine, and 1 filling the wells per machine. So 4 shifts per day. Automated reporting into LMIS system - electronic connection into health records automatically.	£200	
Lab supervisors	supervising lab	579	two one for each lab (one for each 9hr shift) - average 10 RT LAMP machines per lab	£300	
Lab staff training	training on running RT LAMP tests	12,153	Initial 2-day training, 1 day refresher every 3 months	£200	5 days training per year
				unit cost	
Recruitment costs	Recruitment costs for all lab staff, including for replacements and cover	12153	£200 per recruitment for advertisements, phone interviews, salary of recruiters	£200	
Overheads					
Lab overheads	Overhead (space) costs for ordinary laboratory with category 2 hood (no biosecurity)	579	Estimated cost of £500 per day per lab for 289 labs with 10 RT LAMP machines in each	£500	

2. Testing - SARS-Cov-2 viral RNA RT LAMP tests, home saliva samples*					
Machines	Function	Number	Rationale for number	RT LAMP machine cost per day	Notes
START-UP COSTS: RT LAMP Machines	SARS-Cov-2 viral RNA RT LAMP testing. Also automatically uploads data to online health records	2,894	Enough RT LAMP machines for 10 million tests a day if running 6 days a week 18 hrs a day, one 96 well plate per 30 minutes (20 min start to finish, and 10 min turn around per run). One RT LAMP machine costs £27,000. Having this as an annual cost assumes all machines will be replaced after 12 months on average	£214,041	Total cost per year based on daily cost. If extending time beyond one year can use this as it is based on daily cost <i>i.e.</i> assumes RT LAMP machine lasts for 1 year or average and will then be replaced
RT LAMP Machine maintenance	maintain working order of the 2894 RT LAMP machines used	2,894	assume maintenance costs averaging £10 per day	£28,935	
Equipment				Unit cost	
Test kits, including reagents	viral RNA RT LAMP tests, home saliva samples. RT LAMP is at room temperature and doesn't require RNA extraction, so less reagents needed	3,120,000,000	10 million tests per day	£3.50	Reagents and materials per test - commercially sensitive source - used for pilot study* costing
Home collection of saliva samples	To collect saliva samples by courier to the lab for testing	3,120,000,000	10 million tests per day ²⁹	£0.50	Home collection by couriers - used for costing for pilot study*
Tests Per Day		10,000,000			
3. Isolation encouragement					
These costs are all covered under 1. Contact tracing.		Number		Unit cost	Notes
There may be additional policing costs estimated at £500 for every infringement requiring police action - estimated at 2000 such infringements per day nationally based on France and Italy		624,000		£500	These costs should all be (more than) covered by the fines levied and received for infringements, so are not included in total costs below




Figure 3. Snapshot of the **web-based interface**, which allows users to explore in more detail the scenarios used in this study.

Table 4. Model parameters.

Parameter	Description	Default Value	Reference
N	Population size (UK population mid-year 2020)	67,886,011	65
c	Average contacts per day pre COVID-19	11	35
β (beta)	Transmission rate per contact	0.0435 on average but fitted across different time points in the epidemic	Estimated from fit to mortality data ⁶⁶
α^{-1} (alpha)	Incubation period (time from exposed to infectious)	5 days	67–70
γ^{-1} (gamma)	Recovery period (time from infection to recovery or hospitalisation)	7 days	71,72
κ^{-1} (kappa)	Isolation period (symptom free days)	14 days	73
θ (theta)	Testing rate of infectious individuals	Varied across scenarios	-
χ (chi)	Contact tracing rate	Varied across scenarios	-
η (eta)	Efficiency or success rate of contact tracing and isolation	Varied across scenarios	-




Figure 4. Results of the model calibration to deaths showing the excellent fit between model-predicted deaths and confirmed COVID-19 deaths from the UK data between 21/01/2020 and 23/10/2020.

(contacts per day) as a proxy for economic activity, for every day of the model scenario trajectory. GDP of £186 billion per month is taken as the pre-pandemic level⁷⁴, when $c = 11$, whereas during lockdown GDP is 25% lower, when $c = 3$. For intermediate values of lockdown or distancing, GDP loss is scaled accordingly. The pandemic itself results in GDP loss, as $c = 80\%$ of baseline even when lockdown is fully released, *i.e.* the country is not back to $c = 11$ (100%) normal economic activity.

Intervention costs

Intervention costs are calculated by dividing the budget items shown in Table 3 by start-up costs and on-going costs: for tracing, and for testing. Costs to notify, enforce, and otherwise manage isolation are assumed to be covered by fines levied for breaches of isolation. Overall start-up costs for contact tracing are £10m for the app that supplements human contact tracing efforts, as well as a recruitment campaign to hire the number of needed contact tracers, supervisors, and managers. Start-up costs include recruitment and training costs for personnel, and app maintenance costs, for which we have made several assumptions detailed in Table 3 and below, though these are small enough not to significantly alter overall costs. On-going costs are scaled according to the numbers required by the intervention by estimating the cost per contact traced and the cost per test, as follows.

Contact tracing costs. Using our assumptions around number of contacts before lockdown ($c_0=11$), during lockdown ($c=0.3*c_0$), and after the lockdown is lifted ($c=0.8*c_0$), we determine that over a period of seven days a total of 77 contacts need to be traced before lockdown, while during lockdown only 23 contacts will need to be traced.

As a policy design assumption for the model, we stipulate that contact tracers and supervisors are hired for a minimum of three months (90 days) for the system to function professionally, while team leads are hired for the entire term of contact tracing. Contact tracing costs are therefore blocked into three-month periods based on the anticipated maximum number of tracers needed in the subsequent three-month period. Recruitment and

training costs for any additional tracers needed in the subsequent three-month period are added to the cost for that three-month period.

The recurring tracing costs can be used to determine a (marginal) cost per hour of tracing, which can then be used to determine the cost per trace given our estimate of 1.26 hours work per contact traced (Table 5). We estimate the cost per contact traced is approximately £18 (calculations as per ‘Tracing costs per case traced’ sheet [here](#)).

Testing costs. We estimate that each test costs £4.79 including start-up and recurring costs. The vast majority of these costs are the £4.50 for each actual test (£3.50 for the test kit, £0.50 for mailing out the test kit, and £0.50 for the courier from the tested person’s address to the local lab). Start-up costs for testing are the cost of the RT-LAMP machines (£27,000 each). Each machine can run 96 tests every 30 minutes⁷⁵ so if we assume they will be running for 18 hours per day (two 9-hour shifts) they will process 3,456 tests per day. We assume 10 machines per lab on average, each with £500 per day overheads, 40 lab workers (four per machine: two for each shift), and two supervisors (one for each shift).

Testing personnel costs are blocked into six-month periods based on the anticipated numbers of tests per day over the subsequent six-month period. In a six-month period where only 100,000 tests are being done each day, costs per test would still be approximately £4.79, as the number of labs, maintenance costs, and lab workers would be scaled down accordingly, and the RT-LAMP machines would be amortized over the full period of use.

Cost of face coverings

We assume that if people are unable to afford their own face coverings they will be wearing reusable face coverings made from materials to hand in the home, at little or no cost. The UK government has issued advice on [how to make and properly use a face covering](#).

Table 5. Hours required to identify contacts of each new case based on European Centre for Disease Prevention and Control guidelines.

Contact tracing resources required for each new case	Public Health Community Officer (PCHO) hours
Interview new case and create list of contacts (45 min - 1 hr)	0.85
Interview 14 high-risk* contacts (20 min each)	4.6
Interview 16 low-risk† contacts (10 min each)	2.7
Monitor 14 high-risk contacts daily for 10 days (10 min per call)	23.3
Monitor 16 low-risk contacts for 10 days (1 min per call)	2.7
Arrange to test symptomatic contacts (a) (10 minutes)	0.6
Car service taking 1 hour to test 50% of symptomatic contacts	3.1
Total hours	37.8
(a) Assume 3.7 symptomatic contacts per new case (URTI prevalence of 42/1000 ⁷⁶ and R_0 of 2.5 ⁷⁷)	

***High-risk** exposure contacts are people having had face-to-face contact with a COVID-19 case within two metres for more than 15 minutes; having had physical contact with a COVID-19 case; having had unprotected direct contact with infectious secretions of a COVID-19 case (e.g. being coughed on); having been in a closed environment (e.g. household, classroom, meeting room, hospital waiting room, etc.) with a COVID-19 case for more than 15 minutes; or a healthcare worker or other person providing care to a COVID-19 case, or laboratory workers handling specimens from a COVID-19 case, without recommended PPE or with a possible breach of PPE⁷⁸.

†**Low-risk** exposure contacts are people having had face-to-face contact with a COVID-19 case within two metres for less than 15 minutes; having been in a closed environment with a COVID-19 case for less than 15 minutes; having travelled together with a COVID-19 case in any mode of transport; or a healthcare worker or other person providing care to a COVID-19 case, or laboratory workers handling specimens from a COVID-19 case, wearing the recommended PPE⁷⁸.

Realising the Resources for different test-trace-isolate strategies

1. Contact tracing

There is emerging evidence that mobile phone contact tracing apps have the potential to facilitate effective COVID-19 epidemic control at scale and at speed¹⁸. Nevertheless, personal follow-up on foot will also be required to ensure all contacts, including the most vulnerable, are reached⁷⁹. The additional costs of such a system are relatively small in the context of the problem we are seeking to address.

For feasibility reasons, we assume that control of COVID-19 would be managed through local authorities by Consultants in Health Protection/Communicable Disease Control and Directors of Public Health. This was the approach used, with success, until the re-organisation in 2002 and it ensured effective control of communicable disease via local knowledge of and relationships with the community, the local politicians and leaders, the laboratory, the hospital and its consultants, and the general practitioners^{80,81}. Legal powers to take such responsibility are available through Schedule 21 (powers relating to potentially infectious persons) of the Coronavirus Act 2020. Regional Health Protection Teams from Public Health England could take

on management responsibilities for local authorities in England (public health functions are already devolved in Scotland, Wales, and Northern Ireland) and co-ordinate regionally and centrally through its established infrastructure. This includes regional epidemiologists who have a key role in understanding the epidemic at a regional level, identifying differences between local authorities, and sharing expertise.

Movement of people between local authority areas could be accounted for by data sharing between contact tracing teams. China, while being different in many ways, demonstrates the ability for this hierarchical approach to succeed in identifying contacts⁸².

Case finding and contact tracing. Contact tracing remains a key control measure for maintaining suppression of case counts⁸³. Table 5 shows the staff needed to handle new cases and control spread through contact tracing and isolation⁸⁴.

The NHS Test and Tracing Service was launched on 29th May. While information on the structure, duties, and means of collaborating with the contact tracing teams in local authorities has not been published, it is reasonable to assume that this

centrally managed service will provide some of the hours required to run the case finding and contact tracing function shown in [Table 5](#). It seems that the service is limited to phone and internet communication with individuals. Because the levels of ascertainment of cases of this approach remains unknown, it will be prudent for local authorities to assume that at least half the manpower shown in [Table 5](#) will be required by them.

Local public health capacity. Each new case will require 38 hours of community health staff and volunteer time to trace an average of 30 contacts and test 3.7 symptomatic contacts, two thirds of whom will have COVID-19⁸⁴ (these numbers reflect a situation when physical distancing measures are in place). The requirement for staff will vary with time as relaxation of physical distancing increases contact numbers or as subsequent physical distancing reduces contact numbers, and should decline if phone applications as used in South Korea⁸⁵ are used by sufficient numbers of individuals here and their accuracy increases (though we do not assume any increase in efficiency or success of contact tracing resulting from use of phone apps). On average there will need to be 5.1 full time trained contact tracers (Public Health Community Officers, PHCO; [Table 3](#)) to cope with each additional concurrent case, though this will vary by the number of contacts per day. The numbers of contact tracers will need to be adjusted accordingly to accommodate part-time working and to cover all seven days of the week, as all contact tracing should be done within one day for each case.

A fraction of health visitor (HV) and environmental health officer (EHO) staff can be redeployed initially to lead local teams of contact tracers⁸⁶. Most local authorities have established volunteer registers⁸⁷ and recently retired HVs and EHOs can also support the contact tracing effort. New staff will also need to be hired, given limited capacity and the existing important duties carried out by HVs and EHOs. The system of contact tracing could be up within weeks with sufficient political will and commitment. We assume that it will be possible for most Directors of Public Health alongside the Public Health Physician secondees from Public Health England to assess if they have control of the spread of the virus in their district a week later. The incidence of new cases will vary between local authorities and regions.

Initially the number of cases can be best estimated from local deaths. As the system gets underway, new cases can be notified in the standard way for notifiable diseases, for which testing is helpful but not necessary. The number of cases will fall as physical distancing succeeds, as in China. An estimated 800 to 1,000 contact tracers would be needed two weeks after peak deaths in the averaged-sized local authority (population ~375,000). We assume this is achievable, given the 750,000 people who have already volunteered to help the NHS tackle the pandemic⁸⁸. Training is assumed to take one day, as is setting up the administrative arrangements using local authority resources. Testing facilities can be negotiated with the local health laboratory (see Testing section below). The local authority will be assumed to take on the public information function.

Community advisory committees and local health communication strategies

The overall success of this strategy rests on the willingness of citizens to engage with and accept the necessity of contact tracing and isolation for 14 symptom-free days if in contact with a case, and of home testing via spit (saliva) samples. Social psychological literature suggests that health communication messaging and health interventions are most effective when anchored to meaningful dimensions of identity and personal experience^{89,90}, which has been affirmed by evidence from previous epidemics including HIV^{91,92} and Ebola⁹³. Community-led and co-production approaches in the context of the COVID-19 response have been lacking⁹⁴, but would be critical in ensuring that local engagement strategies result in significant uptake of testing, tracing and isolation over time. We therefore suggest that each local area develop a community advisory committee, whose role is to advise on the suitability of the national plan in their area, and to support the design of a local public health communications strategy tailored to specific subpopulations. It is critical that this group is composed of individuals from the full range of ethnic and cultural backgrounds within the area, given the importance of identity and context to the promotion of positive health behaviours, and the existing marginalisation of subgroups of the population. A life course approach would also ensure that any and all messaging was targeted to the specific needs and concerns facing individuals across the life course.

At the outset, community advisory committees may need to meet regularly (*e.g.* weekly to co-develop communication materials); but over time, its role could transition to helping provide an accountability loop between communities and implementers and managers of the TTI programme, which would require less regular contact. In this way, community members are able to feed details of emergent challenges and difficulties that people face in adhering to cycles of lockdown, real-time data on the efficacy of support systems, and ability to adhere to testing requirements over time. These groups could be coordinated by Public Health COVID-19 supervisors (see below).

There are relevant concerns about how much time it would take to set up these groups in each area. However, each local entity will have a range of third and voluntary sector organisations who are already working to support various communities affected by the crisis. Rapid assessments and mapping of existing community networks by public health agencies would allow for a quick deployment of existing and active community groups in each area, to take control of recruiting relevant people from various backgrounds to engage with the committee.

The task of the supervisor will be to create an overarching structure to coordinate their efforts in a unified structure. In times of lockdown where participatory engagement is limited or restricted, evolving frameworks for how to conduct remote participatory research and community engagement could be adapted⁹⁵. Such a community mechanism will have wide-reaching benefits, including; maintaining local buy-in over time, appropriately tailoring engagement strategies and innovating over

time to maintain engagement, and helping citizens to feel as though they are a part of a wider process for promoting collective wellbeing. The latter has been shown as critical in other crisis and recovery focused settings^{96,97} and can have positive knock on effects for mental health outcomes in the general population, which is a growing concern in the crisis⁹⁸.

Contact tracing budget. One Public Health Community Officer (PHCO) will need to be recruited per 1,000 population (the exact number needed to be recruited in each three month block depends on the number of infections as explained in the economic model section), with budget for 20% extra posts included to cover sickness and absence to help ensure contact tracing always meets demand. These people should be familiar enough with their community to identify individuals disconnected from government reach and internet apps. They could be unemployed or under-employed lay people, including those made redundant due to the pandemic. No prior public health experience or skills will be required beyond minimal educational attainment and having been resident in their local area for at least a year, though ability to speak appropriate languages will be relevant for some communities. The PHCOs could be trained via a short online course delivered by public health professionals and will undergo online refresher training every month. PHCOs will be paid a living wage of £10 per hour, £80 per day for an 8hr shift.

PHCOs will be supervised by full-time Public Health COVID-19 Supervisors (PHCS), at a ratio of 1 supervisor per 50 PHCOs. These PHCSs could be graduates of master's degrees in public health or related disciplines and appointed if they can pass a simple test about control of the COVID-19 epidemic in line with this strategy; or, if sufficient numbers are available and they would not be taken away from important existing duties, they could be Environmental Health Officers. They will be based in COVID-19 offices in their local authority area. Given 343 local authorities in the UK, each will have around 3 or 4 PHCS. PHCS will be paid £20 per hour, £160 per day.

Each local authority will need a COVID-19 response team lead overseeing this effort. The team lead will directly manage and supervise the PHCS and have an overview of the COVID-19 situation in their local authority area. They will be public health specialists with at least five years of experience, perhaps already in post in the local authority area. Importantly, their duties will only relate to the COVID-19 contact tracing, testing and isolation strategy. Therefore, if already in post they will be relieved of other public health duties (and an additional public health lead recruited to oversee such duties) – or perhaps less disruptively, individuals without existing duties will be recruited to lead the COVID-19 response in their local area.

The importance of an integrated system with all workers solely focusing on COVID-19 needs to be emphasised. It is likely to be necessary to ensure the consistently high levels of contact tracing, testing and isolation required.

Mobile phone costs and travel costs are included for all cadres as needed.

2. Testing – SARS-Cov-2 viral RNA RT LAMP tests to detect active infection via home saliva samples

A population-wide testing programme⁹⁹ is a core component of population-wide TTI. This would require the following resources, which are either currently available or can be sourced from UK suppliers within a matter of weeks:

1. A register of names, dates of birth, and addresses of all residents registered with a GP, to be updated as necessary with test results, changes of address and addition of unregistered subjects. Anonymous registration with local outlets for sample collection and delivery is needed for those reluctant to give name and address. “Ghost patients”¹⁰⁰ can be dealt with using the strategy developed by the ONS.
2. New 96-well machines running direct RT LAMP assays¹⁰¹ 18hrs per day processing 96 samples every 30 minutes. Experienced staff to operate them are already in place in large and small academic and commercial labs throughout the UK, including possible demonstration sites. Posts for four 9-hour shifts for lab workers will be needed: 1 technician running each machine and 1 filling the wells with samples.
3. Self-sample spit (saliva) test kits including sample transport tubes individually labelled with name, date of birth, and barcoded ID, LAMP reagents (note RT LAMP does not require the RNA extraction step so needs less reagents), and microtiter plates for 10 million tests per day. Additional production facilities must be commissioned if necessary (Box 1).
4. Arrangements to deliver and collect samples from every household once a week, with delivery to a testing lab within a few hours. Results would be directly uploaded online automatically by the RT LAMP machine into a LIMS system as the sample is diagnosed by the machine, coupled with auto texting of negative results using software already in place. Positive results in those without phone or email would be delivered by courier.
5. This high throughput would depend on various regulatory emergency waivers:
 1. Lab staff would wear PPE where necessary but would not be accredited to conduct medical tests.
 2. Laboratories would be advised on precautions but not accredited for handling infectious samples.
 3. LAMP reagent production with normal non-medical quality control cannot be hampered by patents or regulations on medical test manufacture.

Box 1. Sourcing reagents and supplies to scale up to millions of tests a day

TTI and UT are ambitious compared to the number of tests currently conducted each day. However, it is in line with international estimates of the scale of testing required^{33,34}. The UK government's five-pillar plan for scaling up COVID-19 testing¹⁰² reaches out to local manufacturers to ramp up testing capability and pharmaceutical companies are also offering to help¹⁰³. The extent to which such capacity can be transformed into sustained delivery of the government's current target of 500,000 swab and antibody tests per day is still unclear.

Studies are underway to confirm that saliva samples collected into simple specimen pots can reliably be used for mass population SARS-CoV-2 testing; if confirmed this would remove the current bottleneck in swab availability. The main testing reagents in short supply are not likely to be the non-biological chemicals used, large enough quantities of which could fairly easily be produced in around three months by industrial chemical companies. Some of these materials are already supplied by large companies such as BASF. The bespoke formulations of the mixtures of bio-based reagents, such as proprietary mastermixes and primers specific to each test kit, are potentially the main bottlenecks¹⁰⁴. It will likely be easier and quicker for the existing manufacturers to scale up production than for a new company to attempt to do so, as the new company will require all of the same ingredients in order to exactly match the bespoke formulation of the specific test kit.

Therefore, the UK government probably needs to coordinate industrial consortia of companies with relevant scale-up capabilities and Good Manufacturing Practice approval, such as Robinson brothers¹⁰⁵ (based in the midlands), and test kit manufacturers, such as New England Biolabs and OptiGene, to ensure there is adequate supply of key reagents. In this way, test kit manufacturers will be enabled to create the quantities of the bespoke proprietary formulations needed for millions of tests a day in the UK.

To ensure manufacturers have adequate incentive to participate, the government could issue "put options" that allow the companies to recoup most of their losses in the event the kits are never used¹⁰⁶. More traditional methods of reducing commercial risk, such as direct purchase orders and public-private partnerships, can also be considered so long as they can be arranged quickly enough.

Initial estimates from an industrial chemist suggest the costs to cover the UK demand, per type of reagent, are on the order of £5-10m. It would require short bespoke use of manufacturing units (equipment) per component, the blending of the final formulation, and finally the development of appropriate logistics. The total cost is estimated to be less than £100m.

Rapid efforts will also be needed to source the swabs required to collect nasal/throat self-samplers and the bar-coded tubes labelled with name and date of birth of all residents, to deliver to every household once a week. Again, option-based guarantees and other de-risking measures could play an important role in ensuring the demand is met¹⁰⁶.

TTI: Test-Trace-Isolate UT: Universal Testing

We recommend evaluation of regular COVID-19 saliva testing of the whole population in an entire city as a demonstration site (preferably several towns and cities), with strict household isolation following a positive test. Isolation ends when all residents test negative at the same time. Everyone else can resume normal life if they choose to. This should be assessed for

feasibility in one or more cities with populations of 200,000–300,000. This experiment could only be achieved after extensive, transparent public engagement leading to widespread public acceptability across all social and economic groups. Economic and educational measures would need to be provided to ensure equity with the non-quarantined population. Although this is an ambitious proposal, it does need to begin as soon as possible, whilst the infection rate is fairly low but rising. The rate at which it then rises or falls compared with the rest of the UK will be apparent within a few weeks. A decision can then be taken on national roll-out, beginning in high-risk areas.

A local population of 200,000 with 90% compliance will require 26,000 tests per day, plus an excess to offer more regular testing for NHS staff and care workers. Whatever the results, these data will enable policy to be based on real-time evidence (instead of modelling assumptions) on new infection rates in the expanding regularly-tested population and the untested remainder. The latter can be monitored by testing population samples as well as by NHS number linkage to hospital diagnoses and GP records. Complementary aspects of PTTI: contact tracing and phone apps will be critical in the unscreened population and may enable testing to be done less frequently as prevalence falls. Testing would be voluntary, but incentives for staying in isolation following a positive test in a household could be considered in line with those suggested by community advisory committees. Helplines would be provided to support households in isolation with access to income compensation, mental health support and food delivery.

These pilot studies, one of which has started on a smaller scale in Southampton with 14,000 people³¹, will show whether PTTI is a practicable way of responding to the COVID-19 epidemic. Even if the epidemic is not completely controlled in pilot studies the establishment of far greater testing and tracing capacity will facilitate other initiatives. Different households would return samples on different days, giving a daily sample of each small area. Depending on the proportion of people tested and cases detected a local outbreak could therefore be detected soon after it occurs, as test results would be automatically uploaded online by each LAMP machine.

A register of everyone registered with a GP (suitably amended to deal with unregistered people and "ghost patients") would be used to deliver and collect saliva (and nasal/throat in a subsample) self-samplers in bar-coded tubes labelled with name and date of birth of all residents to every household once a week. The register would be expanded to include any missing people who are subsequently identified (with unique ID numbers for those with no NHS number) and continuously updated to assign people to the household of their current address. Many "households" would have one resident.

Households would self-isolate on the day that any resident gets a positive test, with earlier self-isolation of a household when anyone in it is thought to have COVID-19 based on a publicised list of diagnostic symptoms, pending the household's next test results.

Contact tracing (above) could be focused on the “hard to reach” population that the uncontrolled epidemic will then be confined to. Anyone not possessing a negative test result dated in the past week would be required to provide a saliva/nasal/throat sample and their name, address and date of birth. They would be added to the register and sent weekly self-sample kits like everyone else. There will be challenges with this, for example, inclusion of the homeless population, that may need to be overcome.

Samples would be analysed on machines in university and commercial labs, if necessary by continuous (24-hour) operation (with very occasional down-time for maintenance), though we have costed 18hr per day operation. Laboratory and testing regulations would have to be set aside to enable the laboratory staff currently using these machines for other purposes to do the testing supported by additional assistants. Strategic planning to identify essential laboratory work that needs to be continued during the COVID-19 crisis will be required. This should consider the opportunity costs of not doing such work, whilst also considering the opportunities and costs of extra shifts to utilise the same equipment, recruitment and training of extra lab staff and potential efficiency gains to existing processes (including those that could be gained via relaxing regulations, along with the potential costs of relaxing such regulations).

One of the key bottlenecks for ramping up testing to such a large scale is the availability of reagents and test kit supplies for the tests. Creative ways of resolving this issue are urgently needed (Box 1).

3. Isolation Support and Enforcement

The team of PHCO and PHCS will follow up all those who test SARS-CoV-2 positive and who therefore require isolation. They will ensure that the people requiring isolation understand they need to stay at home for the required period in order to not spread the virus, and steps will be taken to ensure that households have the resources necessary to comply with isolation in the first instance. The costs of policing any infringements will be met by the fines levied for such infringements (likely with surplus funds left over). Therefore, no costs are added for isolation encouragement and enforcement.

For isolation support and enforcement to work without disadvantaging marginalised groups further the following will need to be put in place:

- 1) financial compensation for time off work to comply with a 14-day isolation order following tracing;
- 2) clear guidelines on the roles and powers that police and other authorities have in enforcing isolation;
- 3) a means-based fine system for infringements of isolation, based on household income levels/earnings;
- 4) development of minimum packages of support that are streamlined to specific vulnerable populations – so support that is provided is bespoke for the needs of each household

during an isolation period (*i.e.* houses where earning levels are not impacted will be offered a different resource package than those where earnings are impacted);

- 5) assurances that basic resources (heating, water, electricity, internet access) will be guaranteed during the period of isolation, and for a one-month period post isolation.

On rare instances where households still break isolation rules, police officers will be put in touch with households in breach of guidelines. Fines will be levied in line with household income levels (there is precedence for this with speeding fines¹⁰⁷).

Data availability

All data used in this paper is included in the tables of the paper or otherwise publicly available and included in our software, linked below.

Software availability

Source code available from: <https://github.com/ptti/ptti/tree/F1000-final>

Archived source code at time of publication: <https://zenodo.org/record/4298847>

License: GNU GPL Version 3+

Contributions

This study was developed by TC, JPG, WW and DM with contributions from DF and RR. A previous version of the work was conceptualised by TC, JP, NA, KMG and PR and initially developed with DF, GY, RB, DM, CaB, EP, MO, MS, MG and RR, with early analysis done by GC and TC. The mathematical model used here was developed by WW, SS and JPG with input from TC and DM. The economic model used here was developed by DM and TC with input from WW, SS, JPG, EP, MG and MS. TC, WW, JPG, SS, GC, CaB, KMG, DF, EP, TH, NG, NC, MS, and MG contributed parameter values used in the model or interpretation. The scenarios used in the study were developed by JPG, TC, DM, WW and KG in discussion with all co-authors. WW, DW and JPG ran the modelling analysis with input from TC. DM and WW ran the economic analysis with input from TC, JPG, EP, MG and MS. JPG drafted this version of the paper with substantial contributions from TC, WW, DM, DF and RR. CaB, KMG, JP, RAB, GY, KO, PJR, TH and GC contributed specific sections of the manuscript. Co-authors provided critical feedback across developing iterations of the paper and have read and approved the final manuscript.

Acknowledgements

The following people have provided helpful comments or suggestions, or have otherwise enabled this work: Katie Brennan, Martin J Buxton, Majid Ezzati, Amy Gimma, Gabriel Goh, Grace Grove, Agnese Iuliano, Christopher Jarvis, Paula Lorgelly, Tara Mangal, Ofir Reich, Justin Shovelain, Mark E Thomas.

References

1. **Coronavirus (COVID-19) in the UK.**
[Reference Source](#)
2. World Health Organisation: **Getting your workplace ready for COVID-19.** 2020.
[Reference Source](#)
3. Aboubakr HA, Sharafeldin TA, Goyal SM: **Stability of SARS-CoV-2 and other coronaviruses in the environment and on common touch surfaces and the influence of climatic conditions: A review.** *Transbound Emerg Dis.* 2020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Morawska L, Milton DK: **It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19).** *Clin Infect Dis.* 2020; **71**(9): 2311–2313.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Leung NHL, Chu DKW, Shiu EYC, *et al.*: **Respiratory virus shedding in exhaled breath and efficacy of face masks.** *Nat Med.* 2020; **26**(5): 676–680.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Sommerstein R, Fux CA, Vuichard-Gysin D, *et al.*: **Risk of SARS-CoV-2 transmission by aerosols, the rational use of masks, and protection of healthcare workers from COVID-19.** *Antimicrob Resist Infect Control.* 2020; **9**(1): 100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Fischer EP, Fischer MC, Grass D, *et al.*: **Low-cost measurement of face mask efficacy for filtering expelled droplets during speech.** *Sci Adv.* 2020; **6**(36): eabd3083.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Chu DK, Akl EA, Duda S, *et al.*: **Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis.** *Lancet.* 2020; **395**(10242): 1973–1987.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Liang M, Gao L, Cheng C, *et al.*: **Efficacy of face mask in preventing respiratory virus transmission: A systematic review and meta-analysis.** *Travel Med Infect Dis.* 2020; **36**: 101751.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Chou R, Dana T, Jungbauer R, *et al.*: **Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings : A Living Rapid Review.** *Ann Intern Med.* 2020; **173**(7): 542–555.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Chernozhukov V, Kasahara H, Schrimpf P: **Causal impact of masks, policies, behavior on early covid-19 pandemic in the U.S.** *medRxiv.* 2020.
[Publisher Full Text](#)
12. Mitze T, Kosfeld R, Rode J, *et al.*: **to wear a face mask or not.** 2020.
[Reference Source](#)
13. Wang X, Ferro EG, Zhou G, *et al.*: **Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers.** *JAMA.* 2020; **324**(7): 703–704.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Xu J, Hussain S, Lu G, *et al.*: **Associations of Stay-at-Home Order and Face-Masking Recommendation with Trends in Daily New Cases and Deaths of Laboratory-Confirmed COVID-19 in the United States.** *Explor Res Hypothesis Med.* 2020; **1**–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Wong SH, Teoh JYC, Leung CH, *et al.*: **COVID-19 and Public Interest in Face Mask Use.** *Am J Respir Crit Care Med.* 2020; **202**(3): 453–455.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. **Balancing lives and livelihoods: relaxation of lockdown needs to be finely balanced - The BMJ.** 2020.
[Reference Source](#)
17. Davies NG, Kucharski AJ, Eggo RM, *et al.*: **Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study.** *Lancet Public Health.* 2020; **5**(7): e375–e385.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Ferretti L, Wymant C, Kendall M, *et al.*: **Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing.** *Science.* 2020; **368**(6491): eabb6936.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Panovska-Griffiths J, Kerr CC, Stuart RM, *et al.*: **Determining the optimal strategy for reopening schools, the impact of test and trace interventions, and the risk of occurrence of a second COVID-19 epidemic wave in the UK: a modelling study.** *Lancet Child Adolesc Health.* 2020; **4**(11): 817–827.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Teslya A, Pham TM, Godijk NG, *et al.*: **Impact of self-imposed prevention measures and short-term government-imposed social distancing on mitigating and delaying a COVID-19 epidemic: A modelling study.** *PLoS Med.* 2020; **17**(7): e1003166.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Giordano G, Blanchini F, Bruno R, *et al.*: **Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy.** *Nat Med.* 2020; **26**(6): 855–860.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Fogli A, Perri F, Ponder M, *et al.*: **Pandemic Control in ECON-EPI Networks.** *medRxiv.* NBER Working Paper 27741. 2020.
[Publisher Full Text](#)
23. Silva PCL, Batista PVC, Lima HS, *et al.*: **COVID-ABS: An agent-based model of COVID-19 epidemic to simulate health and economic effects of social distancing interventions.** *Chaos Solitons Fractals.* 2020; **139**: 110088.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Sturniolo S, Waites W, Colbourn T, *et al.*: **Testing, tracing and isolation in compartmental models [In Press].** *PLoS Computational Biology.* 2020.
[Publisher Full Text](#)
25. Scientific Advisory Group for Emergencies: **SAGE meetings.** 2020.
[Reference Source](#)
26. Kucharski AJ, Klepac P, Conlan AJK, *et al.*: **Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study.** *Lancet Infect Dis.* 2020; **20**(10): 1151–1160.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Hellewell J, Abbott S, Gimma A, *et al.*: **Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts.** *Lancet Glob Health.* 2020; **8**(4): e488–e496.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Flaxman S, Mishra S, Gandy A, *et al.*: **Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.** *Nature.* 2020; **584**(7820): 257–261.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Peto J: **Covid-19 mass testing facilities could end the epidemic rapidly.** *BMJ.* 2020; **368**: m1163.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Peto J, Carpenter J, Smith GD, *et al.*: **Weekly COVID-19 testing with household quarantine and contact tracing is feasible and would probably end the epidemic.** *R Soc Open Sci.* 2009; **7**(6): 200915.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. **New saliva test for coronavirus piloted in Southampton.**
[Reference Source](#)
32. Iacobucci G: **Covid-19: Mass population testing is rolled out in Liverpool.** *BMJ.* 2020; **371**: m4268.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. **Roadmap to Pandemic Resilience.**
[Reference Source](#)
34. **Roadmap to Responsibly Reopen America.**
[Reference Source](#)
35. Klepac P, Kucharski AJ, Conlan AJK, *et al.*: **Contacts in context: large-scale setting-specific social mixing matrices from the BBC Pandemic project.** *medRxiv.* 2020; 2020.02.16.20023754.
[Publisher Full Text](#)
36. **A Compendium of Models that Predict the Spread of COVID-19.**
[Reference Source](#)
37. O'Driscoll M, Santos GRD, Wang L, *et al.*: **Age-specific mortality and immunity patterns of SARS-CoV-2.** *Nature.* 2020.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Cummins L, Ebyarimpa I, Cheetham N, *et al.*: **Factors associated with COVID-19 related hospitalisation, critical care admission and mortality using linked primary and secondary care data.** *Medrxiv preprint (to appear).* MEDRxIV/2020/241844.
39. Yong E: **COVID-19 Can Last for Several Months.** *The Atlantic.* 2020.
[Reference Source](#)
40. Colbourn T, Waites W, Manheim D, *et al.*: **ptti/ptti: Modelling the health and economic impacts of different testing and tracing strategies for COVID-19 in the UK (Version F1000-final).** *Zenodo.* 2020.
[Publisher Full Text](#)
41. Colbourn T, Waites W, Raine R, *et al.*: **Modelling the Health and Economic Impacts of Population-Wide Testing, Contact Tracing and Isolation (PTTI) Strategies for COVID-19 in the UK.** 2020.
[Publisher Full Text](#)
42. Bloom EA, de Wit V, Carangal-San Jose MJF: **Potential Economic Impact of an Avian Flu Pandemic on Asia.** 2005.
[Reference Source](#)
43. **CoMix study - Social contact survey in the UK.** 2020.
[Reference Source](#)
44. <https://coviddatahub.com>.
45. **Unmasked retail staff putting off customers, says survey.**
[Reference Source](#)
46. Taylor D, Brooks L, Halliday J: **Nine out of ten public transport users wearing face masks - survey.** *The Guardian.* 2020.
[Reference Source](#)
47. **BTP.**
[Reference Source](#)

48. Smith M: **COVID-19: Britons still won't wear face masks.** 2020. [Reference Source](#)
49. Verma S, Dhanak M, Frankenfield J: **Visualizing the effectiveness of face masks in obstructing respiratory jets.** *Phys Fluids (1994)*. 2020; **32**(6): 061708. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. MacIntyre CR, Seale H, Dung TC, *et al.*: **A cluster randomised trial of cloth masks compared with medical masks in healthcare workers.** *BMJ Open*. 2015; **5**(4): e006577. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Douglas M, Katikireddi SV, Taulbut M, *et al.*: **Mitigating the wider health effects of covid-19 pandemic response.** *BMJ*. 2020; **369**: m1557. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Richards M, Anderson M, Carter P, *et al.*: **The impact of the COVID-19 pandemic on cancer care.** *Nature Cancer*. 2020; **1**: 565–567.
53. Maringe C, Spicer J, Morris M, *et al.*: **The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.** *Lancet Oncol*. 2020; **21**(8): 1023–1034. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Saxena S, Skirrow H, Bedford H: **Routine vaccination during covid-19 pandemic response.** *BMJ*. 2020; **369**: m2392. [PubMed Abstract](#) | [Publisher Full Text](#)
55. Lee J: **Mental health effects of school closures during COVID-19.** *Lancet Child Adolesc Health*. 2020; **4**(6): 421. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Hall KS, Samari G, Garbers S, *et al.*: **Centring sexual and reproductive health and justice in the global COVID-19 response.** *Lancet*. 2020; **395**(10231): 1175–1177. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Kluge HHP, Wickramasinghe K, Rippin HL, *et al.*: **Prevention and control of non-communicable diseases in the COVID-19 response.** *Lancet*. 2020; **395**(10238): 1678–1680. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Tsai J, Wilson M: **COVID-19: a potential public health problem for homeless populations.** *Lancet Public Health*. 2020; **5**(5): e186–e187. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Wang H, Li T, Barbarino P, *et al.*: **Dementia care during COVID-19.** *Lancet*. 2020; **395**(10231): 1190–1191. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Armitage R, Nellums LB: **The COVID-19 response must be disability inclusive.** *Lancet Public Health*. 2020; **5**(5): e257. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Kinner SA, *et al.*: **Prisons and custodial settings are part of a comprehensive response to COVID-19.** *Lancet Public Health*. 2020; **5**(4): e188–e189. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Martinez-Juarez LA, Sedas AC, Orcutt M, *et al.*: **Governments and international institutions should urgently attend to the unjust disparities that COVID-19 is exposing and causing.** *EClinicalMedicine*. 2020; **23**: 100376. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Aldridge RW, Lewer D, Katikireddi SV, *et al.*: **Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data [version 2; peer review: 3 approved].** *Wellcome Open Res*. 2020; **5**: 88. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Rogers JP, Chesney E, Oliver D, *et al.*: **Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic.** *Lancet Psychiatry*. 2020; **7**(7): 611–627. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. **U.K. Population (2020) - Worldometer.** [Reference Source](#)
66. **Coronavirus (COVID-19) in the UK.** [Reference Source](#)
67. Davies NG, Klepac P, Liu Y, *et al.*: **Age-dependent effects in the transmission and control of COVID-19 epidemics.** *medRxiv*. 2020; 2020.03.24.20043018. [Publisher Full Text](#)
68. Lauer SA, Grantz KH, Bi Q, *et al.*: **The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application.** *Ann Intern Med*. 2020; **172**(9): 577–582. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Wilder-Smith A, Chiew CJ, Lee VJ: **Can we contain the COVID-19 outbreak with the same measures as for SARS? *Lancet Infect Dis*. 2020; **20**(5): e102–e107. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)**
70. Li Q, Guan X, Wu P, *et al.*: **Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.** *N Engl J Med*. 2020; **382**(13): 1199–1207. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Woelfel R, Corman VM, Guggemos W, *et al.*: **Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster.** *Infectious Diseases (except HIV/AIDS)*. 2020. [Publisher Full Text](#)
72. Bhatraju PK, Ghassemieh BJ, Nichols M, *et al.*: **Covid-19 in Critically Ill Patients in the Seattle Region - Case Series.** *N Engl J Med*. 2020; **382**(21): 2012–2022. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
73. **Considerations for quarantine of individuals in the context of containment for coronavirus disease (COVID-19).** [Reference Source](#)
74. Focus S: **UK Economic Outlook.** [Reference Source](#)
75. Genie® HT OptiGene: *OptiGene.* [Reference Source](#)
76. Global Health Data Exchange: **GHDx.** 2020; [cited 2020 Apr 8]. [Reference Source](#)
77. European Centre for Disease Prevention and Control: **Rapid risk assessment: Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK - eighth update.** 2020; [cited 2020 Apr 9]. [Reference Source](#)
78. Leung K, Wu JT, Liu D, *et al.*: **First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment.** *Lancet*. 2020; **395**(10233): 1382–1393. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. Eames KT, Webb C, Thomas K, *et al.*: **Assessing the role of contact tracing in a suspected H7N2 influenza A outbreak in humans in Wales.** *BMC Infect Dis*. 2010; **10**: 141. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
80. Pollock AM, Roderick P, Cheng KK, *et al.*: **Covid-19: why is the UK government ignoring WHO's advice? *BMJ*. 2020; **368**: m1284. [PubMed Abstract](#) | [Publisher Full Text](#)**
81. Bowie C, Hill T: **Rapid response to Covid-19: why is the UK government ignoring WHO's advice? *BMJ*. 2020; **368**: m1284. [Publisher Full Text](#)**
82. WHO-China Joint Mission: **Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19).** 2020; [cited 2020 Apr 7]. [Reference Source](#)
83. European Centre for Disease Prevention and Control: **Contact tracing: Public health management of persons, including healthcare workers, having had contact with COVID-19 cases in the European Union - first update.** 2020. [cited 2020 Apr 5]. [Reference Source](#)
84. European Centre for Disease Prevention and Control: **Contact tracing for COVID-19: current evidence, options for scale-up and an assessment of resources needed.** 2020; [cited 2020 May 8]. [Reference Source](#)
85. **Flattening the curve on COVID-19 - How Korea responded to a pandemic using ICT 상세보기** Notice Consulate General of the Republic of Korea in Houston. [Reference Source](#)
86. Public Health England: **Best start to life and beyond; improving public health outcomes for children, young people and families.** 2018. [Reference Source](#)
87. Devon County Council: **Community advice, Coronavirus advice in Devon.** 2020; [cited 2020 Apr 8]. [Reference Source](#)
88. NHS England: **NHS England » NHS volunteer responders: 250,000 target smashed with three quarters of a million committing to volunteer.** [Reference Source](#)
89. Ehret PJ, LaBrie JW, Santerre C, *et al.*: **Self-affirmation and motivational interviewing: integrating perspectives to reduce resistance and increase efficacy of alcohol interventions.** *Health Psychol Rev*. 2015; **9**(1): 83–102. [PubMed Abstract](#) | [Publisher Full Text](#)
90. McDonald RI, Fielding KS, Louis WR: **Conflicting social norms and community conservation compliance.** *J Nat Conserv*. 2014; **22**(3): 212–216. [Publisher Full Text](#)
91. Cornish F, Campbell C: **The social conditions for successful peer education: a comparison of two HIV prevention programs run by sex workers in India and South Africa.** *Am J Community Psychol*. 2009; **44**(1–2): 123–135. [PubMed Abstract](#) | [Publisher Full Text](#)
92. Jaspal R, Lopes B, Maatouk I: **Social Identity and Attitudes toward HIV Pre-exposure Prophylaxis: A Structural Equation Model.** *J Soc Serv Res*. 2020; **46**(3): 331–344. [Publisher Full Text](#)
93. Parker M, Hanson TM, Vandi A, *et al.*: **Ebola and Public Authority: Saving Loved Ones in Sierra Leone.** *Med Anthropol*. 2019; **38**(5): 440–454. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
94. Marston C, Renedo A, Miles S: **Community participation is crucial in a pandemic.** *Lancet*. 2020; **395**(10238): 1676–1678. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
95. Lupton (editor) D: **Doing Fieldwork in a Pandemic (crowd-sourced document).** [Reference Source](#)
96. Burgess RA, Fonseca L: **Re-thinking recovery in post-conflict settings: Supporting the mental well-being of communities in Colombia.** *Glob Public Health*. 2020; **15**(2): 200–219. [PubMed Abstract](#) | [Publisher Full Text](#)

97. Hargreaves J, Davey C, Group for lessons from pandemic HIV prevention for the COVID-19 response: **Three lessons for the COVID-19 response from pandemic HIV**. *Lancet HIV*. 2020; **7**(5): e309–e311.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Holmes EA, O'Connor RC, Perry VH, *et al.*: **Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science**. *Lancet Psychiatry*. 2020; **7**(6): 547–560.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. Peto J, Alwan NA, Godfrey KM, *et al.*: **Universal weekly testing as the UK COVID-19 lockdown exit strategy**. *Lancet*. 2020; **395**(10234): 1420–1421.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
100. Baker C: **Population estimates & GP registers: why the difference?** 2016.
[Reference Source](#)
101. Udugama B, Kadhiresan P, Kozlowski HN, *et al.*: **Diagnosing COVID-19: The Disease and Tools for Detection**. *ACS Nano*. 2020; **14**(4): 3822–3835.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
102. Department of Health and Social Care [UK government]: **Coronavirus (COVID-19) Scaling up our testing programmes**. 2020.
[Reference Source](#)
103. Gsk: **Supporting UK national effort to boost COVID-19 testing**. 2020.
[Reference Source](#)
104. Mehta A: **Mystery surrounds UK claim of Covid-19 test reagent 'shortage'**. *Chemistry World*. 2020.
[Reference Source](#)
105. Robinson Brothers: **Contract Manufacture**. 2020.
[Reference Source](#)
106. Manheim D, Foster D: **Option-based guarantees to accelerate urgent, high-risk vaccines: a new market-shaping approach [version 1; peer review: 1 approved, 1 approved with reservations]**. *F1000Res*. 2020; **9**: 1154.
[Publisher Full Text](#)
107. Government Digital Service: **Speeding penalties**. 2011.
[Reference Source](#)

Open Peer Review

Current Peer Review Status: 

Version 1

Reviewer Report 15 March 2021

<https://doi.org/10.5256/f1000research.30947.r78273>

© 2021 Hauck K. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 **Katharina Hauck** 

MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK

The paper models a test-trace-isolate (TTI) strategy (testing symptomatic people, tracing and isolating everyone) and a strategy where TTI is combined with universal testing (UT; i.e. additional population testing to identify asymptomatic cases). The study projects public health impacts, as the number of infected, isolated and dead individuals, for the United Kingdom between December 2020 and May 2021. The model also projects some economic impacts, comprising of the economic costs of shutdowns in terms of GDP loss, and the direct costs of the TTI strategy. The findings are that TTI and particular a month-long UT campaign over December have a positive impact on the pandemic trajectory, and economic savings. The authors conclude that increased TTI is necessary to suppress the virus and protect the economy, and UT would have a dramatic impact and suppress the effective reproductive number below one.

It is great that the authors attempt to assess the combined public health and economic impact of the pandemic and testing strategies. However, I have several concerns with the modelling that undermines my confidence in the optimistic assessment of the efficacy of TTI in sending the pandemic into reverse.

Transmission of SARS-CoV-2 is modelled with a deterministic compartmental model of diagnosed and undiagnosed compartments. The model is fitted to deaths between January 2020 and October 2020, which means transmission probability, the uniform contact rate, the TTI efficacy required to constrain the pandemic, and other parameters are fitted values. A problem with fitting to earlier deaths data is that the meanwhile prevalent variants with their higher transmissibility are not considered, potentially resulting in an underestimate of transmission dynamics in the model. Neither asymptomatic infection nor varying severity are considered as separate compartments. I see this as a limitation of the model because the modelling of asymptomatic infections seems crucial in projections of a TTI strategy, the efficacy of which is strongly affected by the proportion of infected individuals coming forward to be tested. The paper assumes that 70% of cases are symptomatic. This estimate is likely too optimistic; recent studies have found that this proportion is probably much lower, maybe only 14% of cases are symptomatic.¹ This would greatly reduce the number of infected that are diagnosed, and the projected efficacy of the TTI intervention in the model. A few other assumptions suggest that the efficacy of TTI and UT may be overestimated in the model, including 100% isolation of all those tested and traced is assumed. There is evidence

that adherence to self-isolation is much lower, possibly as low as 18%.² The optimistic assumption on 100% isolation would overestimate the efficacy of TTI and UT in reducing transmissions. I believe the authors would need to revisit their parameter assumptions in light of recent evidence and redo their projections before they can draw reliable policy conclusions.

There is little detail given on the nature of the weekly UT intervention, which according to the findings prevents a further 90,000 deaths and reduces economic loss by £454 billion over the projection horizon. It is not clearly mentioned whether the authors assume weekly testing of the whole UK population over the month of December, i.e., 4 testing rounds of 67 million individuals? Table 1 suggests that UT would require maximum daily tests of 10 million (compared to 69,000 for TTI alone), add £1bn to the total tracing costs (over £13bn of TTI alone), require 20,000 additional tracers (over the 140,000 of TTI alone), and cost £7bn (compared to £55m of TTI). I wonder whether it is worthwhile to analyse UT of the whole population, considering that implementation of such an extensive policy seems infeasible. What about analysing UT of school children, as currently implemented in the UK, or of visitors of high-contact events?

GDP loss is determined by the contact rate as an indicator of economic exchange, with the minimum 'lockdown' contact rate scaled to a maximum GDP loss of 15% as observed during full lockdown. The GDP loss calculation is very simplified and does not consider recent advances on the sophisticated integrated modelling of epidemiological and economic outcomes that consider differential contact rates by economic sectors, sectoral interdependencies, demand shocks, reduced work productivity due to sickness and home working, monetary valuation of loss of life, disruptions of international trade,^{3,4} and others. The intervention costs of TTI and UT are added to the economic assessment, but apart from that, no other costs are considered. The methods section in the appendix contains a very comprehensive and careful exposition of the testing strategies, the resources required and their costs. This part of the paper strikes me as a strong contribution to the existing literature on SARS-CoV-2 testing.

Overall, I am sceptical that the optimistic conclusions on the efficacy and cost-savings associated with TTI and UT are justified by the modelling as it is currently specified. An obvious reality not considered by the model is the current vaccination rollout. The policy relevance of the study is compromised by not including vaccinations, as they will have a substantial impact on the comparative attractiveness of investments into TTI and UT.

References

1. Petersen I, Phillips A: Three Quarters of People with SARS-CoV-2 Infection are Asymptomatic: Analysis of English Household Survey Data. *Clin Epidemiol.* 2020; **12**: 1039-1043 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Smith L, Potts H, Amlôt R, Fear N, et al.: Adherence to the test, trace and isolate system: results from a time series of 21 nationally representative surveys in the UK (the COVID-19 Rapid Survey of Adherence to Interventions and Responses [CORSAIR] study). *medRxiv.* 2020. [Publisher Full Text](#)
3. Pichler A, Pangallo M, del Rio-Chanona R, Lafond F, et al.: Production Networks and Epidemic Spreading: How to Restart the UK Economy?. *SSRN Electronic Journal.* 2020. [Publisher Full Text](#)
4. Baqaee D, Farhi E, Mina M, Stock J: Reopening Scenarios. 2020. [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Economics of infectious diseases

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 01 Apr 2021

Tim Colbourn

Author response (bold) to reviewers comments (plain text)

The paper models a test-trace-isolate (TTI) strategy (testing symptomatic people, tracing and isolating everyone) and a strategy where TTI is combined with universal testing (UT; i.e. additional population testing to identify asymptomatic cases). The study projects public health impacts, as the number of infected, isolated and dead individuals, for the United Kingdom between December 2020 and May 2021. The model also projects some economic impacts, comprising of the economic costs of shutdowns in terms of GDP loss, and the direct costs of the TTI strategy. The findings are that TTI and particular a month-long UT campaign over December have a positive impact on the pandemic trajectory, and economic savings. The authors conclude that increased TTI is necessary to suppress the virus and protect the economy, and UT would have a dramatic impact and suppress the effective reproductive number below one.

It is great that the authors attempt to assess the combined public health and economic impact of the pandemic and testing strategies. However, I have several concerns with the modelling that undermines my confidence in the optimistic assessment of the efficacy of TTI in sending the pandemic into reverse.

Thank you for your review of our paper. We are glad you like the ambition of our paper though we disagree that the paper should be not approved based on our choice of parameter values, when those values reflect the situation in November 2020 when we finalised this paper. Further changes to the model parameters are possible via the web interface we developed for our model, associated with and referenced in the

paper. The underlying compartmental model estimating TTI was published in PLOS Computational Biology on 4th March 2021. Thanks also for highlighting recent advances in joint epidemiological and economic modelling. A recent review of this was recently prepared and submitted for publication by some of the authors (Jasmina Panovska-Griffiths and Mark Sculpher) and hence we are aware of these. But we note that including these amendments is beyond the scope of this piece, which was only intended to illustrate the joint impact on health and the economy of TTI strategies. We agree that with the reality of vaccines and variants since mid-late December 2020 the nature of the epidemic has moved on considerably since we finished this paper, but while in principle we can extend the work to accommodate these, we are unable to significantly revise the model. Doing so is of course possible in theory, but unfortunately requires a complete reworking to account for several changes that have occurred which our calibration would need to change to reflect. Hence, we ask the reviewer to please view this piece of work as a standalone assessment of the COVID-19 situation in the UK in early autumn 2020, which we strongly feel is publication worthy.

Transmission of SARS-CoV-2 is modelled with a deterministic compartmental model of diagnosed and undiagnosed compartments. The model is fitted to deaths between January 2020 and October 2020, which means transmission probability, the uniform contact rate, the TTI efficacy required to constrain the pandemic, and other parameters are fitted values. A problem with fitting to earlier deaths data is that the meanwhile prevalent variants with their higher transmissibility are not considered, potentially resulting in an underestimate of transmission dynamics in the model.

As per our previous comment, this study was completed in mid-November 2020, before the emergence of the B.1.1.7. UK (Kent) variant, or any other virus variants and hence the spillover effect from these on transmissibility and severity is not incorporated. We therefore do not consider this to be an issue making our paper unworthy of publication.

Neither asymptomatic infection nor varying severity are considered as separate compartments. I see this as a limitation of the model because the modelling of asymptomatic infections seems crucial in projections of a TTI strategy, the efficacy of which is strongly affected by the proportion of infected individuals coming forward to be tested.

Our universal testing (UT) scenario covers asymptomatic and symptomatic infected people alike and does not require individuals to “come forward”. It is akin to the twice weekly LFD tests currently recommended for all secondary school children to identify asymptomatic as well as symptomatic cases. For testing targeted by symptoms, this simply means that a smaller proportion of cases are tested. It is correct that we do not represent a difference in propensity to transmit between these two groups as that was not known at the time and there remains uncertainty about this.

The paper assumes that 70% of cases are symptomatic. This estimate is likely too optimistic; recent studies have found that this proportion is probably much lower, maybe only 14% of cases are symptomatic.¹ This would greatly reduce the number of infected that are

diagnosed, and the projected efficacy of the TTI intervention in the model.

This assumption is in line with all modelling studies to date- both published and preprints. We agree with the reviewer that if the proportion who were symptomatic was lower then TTI would indeed be less effective, though UT would remain effective as would still identify cases whether they were asymptomatic or symptomatic.

A few other assumptions suggest that the efficacy of TTI and UT may be overestimated in the model, including 100% isolation of all those tested and traced is assumed. There is evidence that adherence to self-isolation is much lower, possibly as low as 18%.² The optimistic assumption on 100% isolation would overestimate the efficacy of TTI and UT in reducing transmissions. I believe the authors would need to revisit their parameter assumptions in light of recent evidence and redo their projections before they can draw reliable policy conclusions.

Our assumption of 100% isolation is a modelling simplification only. Lower proportions isolated are easily though implicitly captured by lowering the testing or tracing rates. We refer the reviewer and readers to the accompanying web interface linked in the paper (generated with Streamlit) where the testing rate, tracing rate and other parameters can be set. We appreciate the reviewer's comments that a broader parameter sweep across the n-dimensional parameter space would give uncertainty bounds and allow us to incorporate a number of other scenarios including balancing test-trace and isolate assumptions. Undertaking such parameter sweeps would only be useful if we were able to rework the model in light of the new reality of vaccines and variants and consequent new policy questions. All of this is beyond the scope of this paper however unfortunately.

There is little detail given on the nature of the weekly UT intervention, which according to the findings prevents a further 90,000 deaths and reduces economic loss by £454 billion over the projection horizon. It is not clearly mentioned whether the authors assume weekly testing of the whole UK population over the month of December, i.e., 4 testing rounds of 67 million individuals? Table 1 suggests that UT would require maximum daily tests of 10 million (compared to 69,000 for TTI alone), add £1bn to the total tracing costs (over £13bn of TTI alone), require 20,000 additional tracers (over the 140,000 of TTI alone), and cost £7bn (compared to £55m of TTI). I wonder whether it is worthwhile to analyse UT of the whole population, considering that implementation of such an extensive policy seems infeasible.

Testing the whole population regularly was proposed and discussed by the UK government as a potential option via "Operation Moonshot" so we don't believe it was beyond the realms of feasibility. Therefore we stand by our decision to model it- again noting we are simulating specific modelling scenarios and not predicting current or future reality.

What about analysing UT of school children, as currently implemented in the UK, or of visitors of high-contact events?

Our model does not distinguish between different groups of the population such as school children or visitors of high-contact events, therefore whilst this would indeed be useful to include, it is beyond the scope of our work.

GDP loss is determined by the contact rate as an indicator of economic exchange, with the minimum 'lockdown' contact rate scaled to a maximum GDP loss of 15% as observed during full lockdown. The GDP loss calculation is very simplified and does not consider recent advances on the sophisticated integrated modelling of epidemiological and economic outcomes that consider differential contact rates by economic sectors, sectoral interdependencies, demand shocks, reduced work productivity due to sickness and home working, monetary valuation of loss of life, disruptions of international trade,^{3,4} and others.

Thank you for highlighting this recent and more advanced work. Our work was only intended to be a simple model to highlight the parallels between health outcomes and economic outcomes and how TTI/UT could be used to achieve both health and economic benefits. It is only a first-order approximation of the economic effects and it is possible to imagine more sophisticated models that capture higher-order effects and feedback mechanisms. These are beyond the scope of our analysis.

The intervention costs of TTI and UT are added to the economic assessment, but apart from that, no other costs are considered. The methods section in the appendix contains a very comprehensive and careful exposition of the testing strategies, the resources required and their costs. This part of the paper strikes me as a strong contribution to the existing literature on SARS-CoV-2 testing.

Thank you - we hope this, and our responses to your other points, would be sufficient for you to "approve" the paper, with reservations. Given we are out of time to work on it further the paper may otherwise remain as a pre- print / grey literature.

Overall, I am sceptical that the optimistic conclusions on the efficacy and cost-savings associated with TTI and UT are justified by the modelling as it is currently specified. An obvious reality not considered by the model is the current vaccination rollout. The policy relevance of the study is compromised by not including vaccinations, as they will have a substantial impact on the comparative attractiveness of investments into TTI and UT.

We again stress to the reviewer that our paper was written before any vaccinations were approved and indeed before vaccine trial results were published, so we were unable to include vaccinations in our study.

- Is the work clearly and accurately presented and does it cite the current literature?

Partly

- Is the study design appropriate and is the work technically sound?

Partly

- Are sufficient details of methods and analysis provided to allow replication by others?

Partly

- If applicable, is the statistical analysis and its interpretation appropriate?

Partly

- Are all the source data underlying the results available to ensure full reproducibility?

Yes

- Are the conclusions drawn adequately supported by the results?

No

We disagree that differences in parameter values should be grounds to say the conclusions are not supported by the results. We believe the conclusions do follow from our results even if you disagree with some of the specific results as indicated above. We also refer the reviewer to our web interface which allows different parameter values to be set and simulations re-run.

Tim Colbourn, David Manheim, William Waites, Jasmina Panovska-Griffiths

Competing Interests: I declare no competing interests

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research